The 2027 RWE Playbook: Regulation, AI & Data Reshape Evidence

Regulators are no longer just asking whether sponsors have real-world data; they're asking whether that data can be traced, defended, and inspected. As FDA and EMA finalize new guidance on RWE, and as the EU MDR transition deadline approaches, trial teams relying on rented datasets or single-source EHR feeds are finding those foundations too thin to support submission or recertification. The gap isn't access to data. It's the ability to explain where that data came from, how it changed hands, and why it can be trusted.

Three architectural decisions now determine whether evidence generation can hold up under scrutiny: how patient identity is resolved across sources, how data is standardized for both analysis and submission, and how AI-assisted curation can be validated rather than taken on faith. BioPharma and MedTech teams face distinct evidentiary bars, and each requires its own path to meet them. For teams facing label expansion, lifecycle evidence requirements, or MDR recertification, the work ahead is to audit existing programs now, before regulatory gaps become inspection findings.